Zacks: Eidos Therapeutics Inc (EIDX) Given $26.00 Average Target Price by Analysts
Eidos Therapeutics Inc (NASDAQ:EIDX) has earned a consensus broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have given a strong buy rating to the company.
Analysts have set a twelve-month consensus price target of $26.00 for the company and are predicting that the company will post ($0.35) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Eidos Therapeutics an industry rank of 85 out of 255 based on the ratings given to its competitors.
A number of analysts have issued reports on EIDX shares. Bank of America reduced their target price on shares of Eidos Therapeutics from $24.00 to $13.00 and set a “neutral” rating for the company in a research note on Monday, October 1st. Zacks Investment Research cut shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 17th. JPMorgan Chase & Co. started coverage on shares of Eidos Therapeutics in a research note on Monday, July 16th. They issued an “overweight” rating and a $36.00 target price for the company. Finally, Barclays started coverage on shares of Eidos Therapeutics in a research note on Monday, July 16th. They issued an “overweight” rating and a $32.00 target price for the company.
Shares of Eidos Therapeutics stock traded up $0.48 during trading on Friday, hitting $12.41. The stock had a trading volume of 206,563 shares, compared to its average volume of 126,271. Eidos Therapeutics has a 1 year low of $8.89 and a 1 year high of $24.75.
Eidos Therapeutics (NASDAQ:EIDX) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.23) by ($1.15). On average, equities research analysts predict that Eidos Therapeutics will post -2.09 earnings per share for the current fiscal year.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Featured Article: Analyzing a company’s cash flow statement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.